BIOMAT Database Logo BIOMAT Database Logo

Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1. 2015

Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, United States; Department of Pathology, Harvard Medical School, Boston, MA 02115, United States.

APOBEC3G (A3G) is a cytidine deaminase that restricts HIV-1 replication by inducing G-to-A hypermutation in viral DNA; deamination-independent mechanisms are also implicated. HIV-1 Vif protein counteracts A3G by inducing its proteasomal degradation. Thus, the Vif-A3G axis is a potential therapeutic target. To identify compounds that inhibit Vif:A3G interaction, a 307,520 compound library was tested in a TR-FRET screen. Two identified compounds, redoxal and lomofungin, inhibited HIV-1 replication in peripheral blood mononuclear cells. Lomofungin activity was linked to A3G, but not pursued further due to cytotoxicity. Redoxal displayed A3G-dependent restriction, inhibiting viral replication by stabilizing A3G protein levels and increasing A3G in virions. A3G-independent activity was also detected. Treatment with uridine or orotate, intermediates of pyrimidine synthesis, diminished redoxal-induced stabilization of A3G and antiviral activity. These results identify redoxal as an inhibitor of HIV-1 replication and suggest its ability to inhibit pyrimidine biosynthesis suppresses viral replication by augmenting A3G antiviral activity.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D010619 Phenazines
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071480 APOBEC-3G Deaminase An APOBEC deaminase that functions as an inhibitor of RETROVIRIDAE replication and inhibits the mobility of RETROTRANSPOSONS via deaminase-dependent and independent mechanisms. It is selective for SINGLE-STRANDED DNA and does not deaminate double-stranded DNA or single or DOUBLE-STRANDED RNA. It exhibits potent antiviral activity against VIF PROTEIN deficient HIV-1 through the creation of hypermutations in the VIRAL DNA. It also has anti-viral activity against SIMIAN IMMUNODEFICIENCY VIRUSES and HEPATITIS B VIRUS. APOBEC-3G Protein,APOBEC-3G dC-dU Editing Enzyme,APOBEC-Related Cytidine Deaminase,APOBEC-Related Protein,APOBEC3G Deaminase,APOBEC3G Protein,CEM15 Protein,APOBEC 3G Deaminase,APOBEC 3G Protein,APOBEC 3G dC dU Editing Enzyme,APOBEC Related Cytidine Deaminase,APOBEC Related Protein,Cytidine Deaminase, APOBEC-Related,Deaminase, APOBEC-3G,Deaminase, APOBEC3G
D000611 Aminobiphenyl Compounds Biphenyl compounds substituted in any position by one or more amino groups. Permitted are any substituents except fused rings. Biphenylamines,Compounds, Aminobiphenyl
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Antiviral activity of polyoxomolybdoeuropate PM-104 against human immunodeficiency virus type 1.
June 1991, Chemical & pharmaceutical bulletin,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.
August 2005, The Journal of general virology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
August 2007, Journal of virology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Antiviral activity of Hawaiian medicinal plants against human immunodeficiency Virus Type-1 (HIV-1).
January 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Antiviral activity of fattiviracin FV-8 against human immunodeficiency virus type 1 (HIV-1).
March 2001, Bioscience, biotechnology, and biochemistry,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Antiviral activity of Rwandan medicinal plants against human immunodeficiency virus type-1 (HIV-1).
January 2002, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
April 2011, Proceedings of the National Academy of Sciences of the United States of America,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
November 2004, Journal of virology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
September 2011, Journal of virology,
Erez Pery, and Ann Sheehy, and N Miranda Nebane, and Vikas Misra, and Marie K Mankowski, and Lynn Rasmussen, and E Lucile White, and Roger G Ptak, and Dana Gabuzda
CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
October 1993, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!